Skip to main content

Asthma, PICU — NIPPV Settings — Clinical Pathway: Inpatient and ICU

Acute Asthma Exacerbation Clinical Pathway — PICU

NIPPV Settings

Non-invasive positive pressure ventilation (NIPPV) is a mode of ventilation utilized in the setting of acute asthma exacerbation which can reduce work of breathing and potentially stent open the lower airways.

It is used for the treatment of critical asthma to decrease work of breathing and improve ventilation. It is considered a temporizing measure while preparing for intubation in patients that are unresponsive and/or have rising CO2.

Initiation

Start BiPAP at moderate settings of 10/5 cm H2O with supplemental oxygen administration to keep SpO2 > 92%. The multidisciplinary critical care team may escalate settings frequently in an effort to reduce work of breathing.

De-escalation

De-escalate in a stepwise fashion highest tier down to tier 1. Patients do not need to transition to CPAP prior to discontinuation on NIPPV for asthma. They can come directly off from Step 1.

NIPPV Steps

  Step 1 (starting)
Any level of CPAP
Step 2 Step 3 Step 4 (Maximal) Additional Considerations
IPAP: Inspiratory positive airway pressure 10 14 16 20 Application of IPAP allows for driving pressure (Delta P) which may improve inspiratory airflow and decrease work of breathing.
EPAP: Expiratory positive airway pressure 5 6 8 10 Inadequate EPAP results in inefficient INSPIRATORY effort. Inspiratory flow will not occur until sufficient negative pleural pressure is created to reopen obstructed airways, increasing work of breathing.

Anxiolysis for NIPPV

Consider anxiolytics when NIPPV not tolerated. Before anxiolytics are administered, ensure that team is prepared for intubation if necessary. Consider choosing one of the following medications:

Medication Patient Population Timing of Initiation Dosing Consideration for Exclusions
Dexmedetomidine   Inability to tolerate NIPPV due to anxiety Initiation of NIPPV 0.2-1 mcg/kg/hr Bradycardia
Ketamine   Inability to tolerate NIPPV due to anxiety Initiation of NIPPV 0.25-1 mg/kg/hr Symptomatic tachycardia, excessive secretions

 

Jump back to top